Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:32:49.445Z.
Calculation as of: 2026-10-06T17:32:49.445Z.
Quote observation: 2026-10-06T17:29:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1f4beac4ac45f8a46ab4983c5a571fa9813be082d6d81805b5cbd768b9d0a60c
PEG RATIO
N/A
Lucyd, Inc
Market Cap
$5.89M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Lucyd, Inc (LUCY) | $5.89M | N/A |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.87M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.99M | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $5.83M | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.96M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.74M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.01M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | N/A |
| Femasys Inc. (FEMY)vs › | $6.22M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.31M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
